Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391505 | 1.00 | NAAA (0.60) | NAAACA12CA1CA2CA9 | |
| SCHEMBL887113 | 1.00 | NAAA (0.60) | NAAACA12CA1CA2CA9 | |
| SCHEMBL26143 | 1.00 | NAAA (0.60) | NAAACA12CA1CA2CA9 | |
| SCHEMBL931393 | 1.00 | NAAA (0.60) | NAAACA12CA1CA2CA9 | |
| SCHEMBL9720411 | 0.89 | ALDH1A1 (0.52) | NAAACA12CA1CA2CA9 | |
| SCHEMBL2701154 | 0.87 | LPAR2 (0.53) | NAAAFAAH | |
| SCHEMBL6185868 | 0.84 | ALDH1A1 (0.48) | NAAACA12CA1CA2CA9 | |
| SCHEMBL27579477 | 0.82 | NAAA (0.52) | NAAACA12CA1CA2CA9 | |
| SCHEMBL8448333 | 0.77 | NAAA (0.58) | NAAACA12CA1CA2CA9 | |
| SCHEMBL375009 | 0.77 | NAAA (0.58) | NAAACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123812-A1 | FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | SHATTUCK LABS, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| EP-4334455-A1 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| EP-4333898-A2 | PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| EP-4121018-A2 | CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | GENEVANT SCIENCES GMBH (CH) | 2023-01-25 | — | — | EP | claimed |
| EP-4103172-A1 | CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | GENEVANT SCIENCES GMBH (CH) | 2022-12-21 | — | — | EP | claimed |
| WO-2021188389-A2 | CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | GENEVANT SCIENCES GMBH (US) | 2021-09-23 | — | — | WO | claimed |
| WO-2021163339-A1 | CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | GENEVANT SCIENCES GMBH (US) | 2021-08-19 | — | — | WO | claimed |
| EP-3634449-A1 | ALPHAVIRUS NEOANTIGEN VECTORS | Gritstone Oncology, Inc. (US) | 2020-04-15 | — | — | EP | claimed |
| EP-3558271-A1 | METHODS FOR AMELIORATING INFUSION REACTIONS | Arbutus Biopharma Corporation (CA) | 2019-10-30 | — | — | EP | claimed |
| WO-2019051257-A2 | METHODS FOR TREATING HEPATITIS B INFECTIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-14 | — | — | WO | claimed |
| EP-2994167-A2 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | Alnylam Pharmaceuticals, Inc. (US) | 2016-03-16 | — | — | EP | claimed |
| EP-2567693-B1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2015-10-21 | — | — | EP | claimed |
| WO-2014182661-A2 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | ALNYLAM PHARMACEUTICALS, INC (US) | 2014-11-13 | — | — | WO | claimed |
| EP-2281041-B1 | SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2014-07-02 | — | — | EP | claimed |
| EP-2567693-A1 | Lipid encapsulated interfering RNA | Protiva Biotherapeutics Inc. (CA) | 2013-03-13 | — | — | EP | claimed |
| EP-2449106-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | Protiva Biotherapeutics Inc. (CA) | 2012-05-09 | — | — | EP | claimed |
| WO-2012000104-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-01-05 | — | — | WO | claimed |
| WO-2011000108-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | claimed |
| EP-1648519-A2 | LIPID ENCAPSULATED INTERFERING RNA | Protiva Biotherapeutics Inc. (CA) | 2006-04-26 | — | — | EP | claimed |
| WO-2005007196-A2 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-01-27 | — | — | WO | claimed |